February 2015
 << <Aug 2017> >>


Who's Online?

Member: 0
Visitor: 1

rss Syndication

Posts sent on: 2015-02-20


Health Care Sector Update For 02/19/2015: Vnda,eprs,cslt -

In company news, Vanda Pharmaceuticals ( VNDA ) declined Thursday after the specialty drugmaker reported a wider-than-expected adjusted net loss and below-consensus revenue during its Q4 ended Dec. 31. Adjusted net loss widened to $13.5 million, or $0.36 per share, from $12.7 million during the same quarter last year and missing the average estimate of two analysts polled by Capital IQ by $0.14 per share. On a GAAP basis, the company earned $69.7 million, or $1.77 per share, reversing a $7.7 million net loss last year. Total revenues rose 75% over year-ago levels to $15.4 million but still trailed the Street view by around $800,000. The company is sneak a peek here projecting FY15 net sales of between $95 million to $110 million, lagging estimates by at least $28.1 million. VNDA shares were down over 13% at $11.29 apiece in late trade, maintaining a 7-cent spread over its session low. The stock has traded within a 52-week range of $8.34 to $19.25 a share, already slipping about 6% over the past 12 months prior to today's decline. In other sector news, (+) EPRS, Initiated with Outperform rating at Wedbush Securities.

Health Care Sector Update for 02/19/2015: WST, SGNT, ARIA -

In health-care stocks news, West Pharmaceutical Services ( WST ) reported Q4 earnings that were just shy of estimates while its guidance range for 2015 earnings and sales range were below expectations. The maker of components and systems for the packaging and delivery of injectable drugs said adjusted earnings rose to $0.45 per diluted share from $0.38 a year ago, shy of the $0.46 average estimate from three analysts polled by Capital IQ. Over the past 52 weeks, the company has traded between $39.11 and $55.29. Sagent Pharmaceuticals ( SGNT ) reported that for Q4 ended Dec. 31, 2014, its earnings improved from the prior-year quarter, while revenue rose 32% and topped analysts' expectations; it also provided revenue guidance for fiscal 2015 in line with estimates. Over the past 52 weeks, the company has traded between $19.45 and $33.60. And ARIAD Pharmaceuticals ( ARIA ) was higher in pre-market after the drugmaker topped revenue estimates in Q4 and reported a narrower-than-expected per-share loss. The company posted a net loss for the quarter of $5.7 million, or $0.03 per share, compared to a net loss of $74.2 million, or $0.40 per share, for the same period in 2013. This is narrower than the $0.14 per-share loss the Street was expecting. Over the past 52 weeks, the company has traded between $4.90 and $9.15. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.
Health Care Sector Update for 02/19/2015: WST, SGNT, ARIA -

Admin · 469 views · Leave a comment